Clinical EfficacyCreto has demonstrated a potentially best-in-class profile in BCG-UNR NMIBC, with an attractive efficacy/safety profile.
Financial PositionCG ended the quarter with $688.4M in cash, cash equivalents, and marketable securities, which should fund the company into H1 2028 and to profitability.
Regulatory StrategyThe company remains on track to initiate the BLA submission, with eligibility for a rolling submission, suggesting a strong regulatory strategy.